Grand River Hospital is a 665-bed hospital serving Waterloo Region, Ontario, Canada, and surrounding communities, primarily through its KW and Freeport Sites, both located in Kitchener. The two sites were independent hospitals that merged to form Grand River Hospital in April 1995.The hospital has 15 specialized programs and services: surgery, children's program, childbirth, medical imaging, mental health and addictions, withdrawal management, medicine, stroke, complex continuing care, rehabilitation, cancer, critical care, renal, emergency, pharmacy and lab. The hospital also provides renal dialysis and cancer satellite programs in Guelph, Palmerston, Fergus and Mt Forest Centre in Guelph, along with the Hazelglen Outreach Mental Health service in Kitchener.On September 22, 2019, Grand River Hospital integrated all of their systems into a new central computer system in order to improve efficiency for patient care.
A female patient in her 60s with bipolar disorder type 1 underwent robot-assisted radical cystectomy with ileal conduit for muscle-invasive bladder cancer. Postoperatively, she continued her regular lithium dose of 600 mg nightly. By postoperative day 4, her lithium level had risen unexpectedly to 1.38 mmol/L, necessitating temporary discontinuation. Lithium was restarted on postoperative day 12 at 300 mg nightly (50% dose reduction), achieving therapeutic levels (0.63 mmol/L) within 3 weeks. She remained psychiatrically and medically stable during 3 months of follow-up. We propose that lithium reabsorption through the absorptive intestinal mucosa of the ileal conduit contributed to the elevated lithium levels and need for dose reduction. Currently, limited guidance exists from urological and psychiatric associations regarding pharmacokinetic interactions in patients with urinary diversion taking lithium. Based on this case, we recommend: increased lithium monitoring in the postoperative period, consideration of prophylactic dose reduction in the acute postoperative period and close psychiatric follow-up for safe re-titration.
Purpose of review: Cardiovascular disease (CVD) accounts for nearly half of deaths among people receiving maintenance hemodialysis. Observational and interventional data suggest that higher serum magnesium, achieved through higher dialysate magnesium concentrations or oral supplementation, may improve cardiovascular outcomes and survival. This review synthesizes current evidence and provides context for an ongoing cluster-randomized trial that is testing whether a center-wide dialysate magnesium concentration of 0.75 mmol/L, versus ≤0.50 mmol/L, delivered as a policy and sustained for up to four years, reduces the risk of major cardiovascular-related hospitalizations. Sources of information: Peer-reviewed articles. Methods: We searched MEDLINE and EMBASE for observational and interventional studies evaluating serum or dialysate magnesium concentrations and cardiovascular outcomes in patients with chronic kidney disease and/or kidney failure. We appraised the methodological quality of interventional trials. This review is divided into four sections: (1) epidemiological associations between serum magnesium concentrations and CVD outcomes, (2) the impact of a higher concentration of dialysate magnesium on CVD outcomes, (3) the impact of oral magnesium supplementation on CVD outcomes, and (4) ongoing trials. Key findings: Twenty studies, including 10 randomized controlled trials, were reviewed. Systematic reviews and meta-analyses show that hypomagnesemia is associated with higher risks of cardiovascular events and all-cause mortality in hemodialysis. Interventional studies indicate that higher dialysate magnesium concentrations or oral supplementation can improve surrogate markers of vascular health, including less vascular calcification and stiffness. Higher dialysate concentrations may also lower cardiovascular mortality. Given encouraging but predominantly surrogate-based evidence, adequately powered randomized trials are warranted. Limitations: Most trials were small, single-center, and of short duration. They relied on surrogate endpoints, and there was heterogeneity in interventions and outcome measures.
Background: Adolescent psychiatric illness is a serious health problem, though the prosocial behaviours of patients presenting with internalizing concerns has gained little attention. The purpose of this study was to explore prosocial behaviours and their correlates in adolescents accessing outpatient psychiatry in a cross-sectional exploratory study. Methods: A survey was administered to patients on their first appointment to outpatient psychiatry. Results: Participants’ (N = 51) reported prosocial behaviours were positively associated with self-care in the final model; bivariate negative associations were evident between prosocial behaviours and attachment problems and peer problems. Conclusions: Adolescent patients might benefit from a clinical focus on self-care, in particular, maintaining positive connections with others.
An elderly man underwent cardiac surgery with heparin anticoagulation; postoperatively, the platelet counts steadily fell, reaching 50×109/L on postoperative day 5 (POD5), prompting testing for heparin-induced thrombocytopenia (HIT) antibodies; brain imaging showed parietal stroke. Screening immunoassay for HIT antibodies yielded a strong-positive result; the platelet activation test (serotonin-release assay) gave an atypical profile (strong serotonin release at 0, 0.1 and 0.3 U/mL heparin with only partial inhibition by a platelet Fc receptor-blocking monoclonal antibody). Anticoagulation was changed to argatroban plus high-dose intravenous immunoglobulin. Persisting hypercoagulability prompted a switch to fondaparinux, with gradual platelet count recovery (155×109/L, POD62); neurological abnormalities resolved. Laboratory evaluation confirmed HIT antibodies with heparin-independent platelet-activating properties, indicating autoimmune HIT (aHIT). Besides profound thrombocytopenia (platelet count nadir, 13×10⁹/L), novel aspects of this case of aHIT include early postoperative onset (before POD5) resulting from preoperative heparin exposure and a unique laboratory aHIT antibody profile with partial resistance to Fc receptor blockade.
Background: In individuals receiving hemodialysis, lower serum magnesium concentrations are associated with a higher risk of death and cardiovascular disease and more discomfort from muscle cramps. Small trials suggest that increasing serum magnesium by using a higher concentration of dialysate magnesium may be beneficial. This protocol outlines a large, randomized trial examining the effects of adopting a high versus low concentration of dialysate magnesium as a hemodialysis center-wide policy on the risk of mortality, major adverse cardiovascular events, and the burden of muscle cramps. Objective: To determine whether implementing a dialysate magnesium concentration of 0.75 mmol/L versus ≤ 0.5 mmol/L as a hemodialysis center-wide policy, for up to 4 years, affects (1) the rate of all-cause mortality or major cardiovascular-related hospitalizations or (2) the level of discomfort individuals experience from muscle cramps. Design: Pragmatic, 2-arm, parallel-group, registry-based, open-label, 2-sided superiority cluster randomized trial. Hemodialysis centers were randomly allocated (1:1) to one of the 2 arms. The assignment was constrained by five center-level prognostic factors and stratified by province. Setting: 137 hemodialysis centers in four Canadian provinces—Ontario, British Columbia, Alberta, and Manitoba. The trial period is from April 4, 2022, to March 31, 2026. Outcomes will be analyzed after March 31, 2026, using provincial health care databases and self-reported questionnaires. Participants: Individuals who received maintenance hemodialysis at participating centers during the trial period. Intervention: Use of a dialysate magnesium concentration of either 0.75 mmol/L or ≤ 0.5 mmol/L as a center-wide policy during the trial period. Measurements: The two primary outcomes are (1) a composite of all-cause mortality or major cardiovascular-related hospitalization (a hospital admission with myocardial infarction, congestive heart failure, or ischemic stroke) recorded in large health care databases and (2) self-reported muscle cramps collected from questionnaires. Methods: Using an intent-to-treat approach, the intervention effect on the instantaneous rate of the primary composite outcome will be analyzed using a stratified Cox proportional hazards model accounting for center-level clustering. The observation time will be censored for provincial emigration or the trial end date. Self-reported muscle cramps will be analyzed using a cumulative link (proportional odds) model. All models will be stratified by province and adjusted for the covariates used to constrain randomization. Limitations: The trial start date was delayed in some centers due to post-pandemic supply disruptions (including discontinued dialysate formulations); however, all centers secured dialysate concentrates in alignment with the trial-allocated magnesium level. Conclusions: The results of this pragmatic trial will inform center-wide policy on the optimal dialysate magnesium concentration for patient health. Trial Registration: www.clinicaltrials.gov ; identifier: NCT04079582